Keyphrases
Immune Modulatory Vaccine
100%
Metastatic Melanoma
100%
Indoleamine 2,3-dioxygenase 1 (IDO1)
100%
Programmed Death
100%
Nivolumab
100%
Confidence Interval
60%
T Cells
40%
Programmed Death-ligand 1 (PD-L1)
40%
Median Progression-free Survival
20%
Immunogenicity
20%
Cancer Cells
20%
Autoreactive T Cells
20%
Anti-PD-1 Therapy
20%
Clinical Potential
20%
Naïve Patients
20%
Immunosuppressive Tumor
20%
Objective Response Rate
20%
Specific Response
20%
Monotherapy
20%
Systemic Toxicity
20%
Median Overall Survival
20%
Therapy-naïve
20%
Anti-programmed death-1 Therapy
20%
Tumor Cells
20%
Clinical Efficacy
20%
First-in-class
20%
Cell-to-cell
20%
Safety Data
20%
CD4+
20%
Immunomodulating
20%
Effective Treatment
20%
Vaccination
20%
Immune Cells
20%
Immunosuppressive Cells
20%
CD8+ T Cells
20%
Randomized Trial
20%
Tumor Site
20%
Patient Progress
20%
Phase 1/2 Study
20%
Complete Response
20%
Toxicity Profile
20%
Medicine and Dentistry
Nivolumab
100%
Indoleamine 2,3 Dioxygenase
100%
Metastatic Melanoma
100%
T Cell
60%
Overall Survival
20%
T-Helper Cell
20%
Immunosuppressive Drug
20%
Malignant Neoplasm
20%
Immunocompetent Cell
20%
Immunogenicity
20%
In Vitro
20%
Monotherapy
20%
Cytotoxic T-Cell
20%
Programmed Death 1 Ligand 1
20%
Tumor Cell
20%
Progression Free Survival
20%
Neoplasm
20%
Immunology and Microbiology
Vaccine Efficacy
100%
Nivolumab
100%
Indoleamine 2,3-dioxygenase
100%
T Cell
60%
Programmed Death 1 Ligand 1
20%
Progression Free Survival
20%
T-Helper Cell
20%
Vaccination Policy
20%
Tumor Cell
20%
Immunosuppressive Drug
20%
Overall Survival
20%
Cytotoxic T-Cell
20%
Cancer Cell
20%
Immunocompetent Cell
20%
Immunogenicity
20%
